Global Obesity Market Landscape Examined by GBI Research in Topical Research Study Available at MarketPublishers.com
30 Nov 2015 • by Natalie Aster
LONDON – Obesity is a major fastest-growing public health concern from pole to pole. With the worldwide prevalence keeping on rising, the disease has put a heavy burden on healthcare spending, as it also acts as a key risk factor for diabetes, cardiovascular diseases and cancer.
Anti-obesity drug therapy can be used as a useful adjunct to lifestyle change to improve weight loss with a view to considerably mitigating obesity-related health risks in obese patients. Nevertheless, the use of presently available anti-obesity medications is heavily limited by a modest weight reduction effect and poor long-term safety performance. In spite of significant regulatory and clinical challenges, the early-stage obesity drug pipeline is still robust, comprising a high degree of first-in-class innovation that is anticipated to be translated into safe and efficient treatments of weight loss.
Topical market research study “Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation” elaborated by GBI Research presents keen insights into the obesity market. It delves deep into the actual clinical and commercial landscape, assessing the pathogenesis, prognosis and diagnosis of the disease, and also the available treatment modalities and their limitations with respect to efficacy and safety. The research report casts light on the unmet needs in the obesity marketplace with a view to gaining a competitive understanding of the most important opportunities. The study presents an all-round assessment of the obesity pipeline by phase of development, type of molecules, and the versatility of molecular targets in the pipeline. A detailed evaluation of the therapeutic potential of first-in-class targets is also provided in the report. The research publication gives an overview of the most promising and novel obesity drug products for early-stage investment by canvassing the trends in co-development and licensing deals and providing an access to a curated listing of first-in-class therapies possibly open to deal-making opportunities.
Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation
Published: October, 2015
Price: US$ 6,995.00
More reports by the publisher can be found at GBI Research page.